In a phase II clinical trial NCT02643550 for the treatment of SCCHN, monalizumab combined with cetuximab, an anti-EGFR monoclonal antibody, resulted in a partial response rate of 31%, and stable disease at 54%, compared with the historical data of 13% objective response rate for single agent cetuximab, showing that NKG2A blockade has the potential of treating tumor patients in combination with tumor-targeting antibodies. This evidence concerns the gene KLRC1 and head and neck squamous cell carcinoma.